Aytu BioScience (AYTU) Reports Enrollment of First 20-Patients in Natesto Spermatogenesis Study

July 17, 2018 8:12 AM
Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)


FDA Management Comments

Next Articles